Back to Search
JAMES SAN MIGUEL, DO
DO
Student in an Organized Health Care Education/Training Program
NPI: 1679214076Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
390200000X(NY)
Research & Publications (20)
Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors.
PMID 19357701·Leukemia·2009
4-observational
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
PMID 18774632·Blood Rev·2009
6-review
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
PMID 19465418·Ann Oncol·2009
6-review
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.
PMID 19457552·Leuk Res·2009
8-other
Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population.
PMID 19508976·Haematologica·2009
8-other
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PMID 19561323·Blood·2009
8-other
A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia.
PMID 19252174·Haematologica·2009
8-other
Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.
PMID 19413677·Oral Dis·2009
6-review
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
PMID 19170677·Br J Haematol·2009
3-trial
Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies.
PMID 19123459·Am J Hematol·2009
8-other
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.
PMID 19398719·Blood·2009
8-other
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease.
PMID 19003959·Int J Cancer·2009
8-other
Frontline treatment in elderly patients with multiple myeloma.
PMID 19389497·Semin Hematol·2009
6-review
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
PMID 19302559·Eur J Haematol·2009
3-trial
Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
PMID 19001321·J Clin Oncol·2008
4-observational
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
PMID 18986387·Br J Haematol·2008
4-observational
Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting.
PMID 18852666·Transplantation·2008
8-other
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
PMID 18815192·Haematologica·2008
8-other
Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy.
PMID 18804047·Biol Blood Marrow Transplant·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 130 E 77TH ST FL 6
NEW YORK, NY 10075 - Phone
- (212) 434-4763
Quick Facts
- NPI
- 1679214076
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile